The cost of clinical trials is rising but is still much less than the cost of not doing trials
Clinical trials have led to significant advances in health outcomes. For example, much of the continued decline in cardiovascular mortality since 2000 has been attributed to the evidence that established the various treatment strategies now in common use.1 However, as the costs of both medical care and clinical trials continue to rise, are our current clinical trials good value for money? In this article, the last in a series based on the MJA Clinical Trials Research Summit, we discuss the need for an innovative funding model for investigator-led clinical trials.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Granger CB, Murray JJ. Using measures of disease progression to determine therapeutic effect: a sirens’ song. J Am Coll Cardiol 2006; 48: 434-437.
- 2. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009; 361: 557-568.
- 3. Cooper DJ, Rosenfeld JV, Murray L, et al; DECRA Trial Investigators, ANZICS Clinical Trials Group. Decompressive craniectomy in diffuse traumatic brain injury. N Engl J Med 2011; 364: 1493-1502.
- 4. Leslie K, Myles PS, Chan MT, et al. Nitrous oxide and long-term morbidity and mortality in the ENIGMA trial. Anesth Analg 2011; 112: 387-393.
- 5. Graham AM, Myles PS, Leslie K, et al. A cost-benefit analysis of the ENIGMA trial. Anesthesiology 2011; 115: 265-272.
- 6. INIS Collaborative Group; Brocklehurst P, Farrell B, King A, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011; 365: 1201-1211.
- 7. Brighton TA, Eikelboom JW, Mann K, et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979-1987.
- 8. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379-1387.
- 9. Tonkin AM, Eckermann S, White H, et al; LIPID Study Group. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. Am Heart J 2006; 151: 1305-1312.
- 10. Chua YJ, Zalcberg JR. Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Rev Anticancer Ther 2008; 8: 595-604.
- 11. Zalcberg JR. Comparative effectiveness research — a proposal for a new NHMRC funding stream. Med J Aust 2012; 196: 22-23. <MJA full text>
- 12. Johnston SC, Rootenberg JD, Katrak S, et al. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 2006; 367: 1319-1327.
- 13. McNeil JJ, Nelson MR, Tonkin AM. Public funding of large scale clinical trials in Australia. Med J Aust 2003; 179: 519-520. <MJA full text>
- 14. Davis ID, Chew DP. Clinical effectiveness research: a critical need for health sector research governance capacity. Med J Aust 2013; 198: 191-192. <MJA full text>
- 15. Martin JH, Theile DE, Ho KK, Frazer IH. Diamantina Health Partners: integrating leadership in clinical research translation, education and clinical care. Med J Aust 2012; 196: 237-239. <MJA full text>
- 16. Dzau VJ, Ackerly DC, Sutton-Wallace P, et al. The role of academic health science systems in the transformation of medicine. Lancet 2010; 375: 949-953.
- 17. Smith S. The value of Academic Health Science Centres for UK medicine. Lancet 2009; 373: 1056-1058.
- 18. Australian Government. The 2010 intergenerational report. http://archive. treasury.gov.au/igr. (accessed May 2013).
- 19. Nelson MR. General practice-based clinical trials. Med J Aust 2013; 198: 136-137. <MJA full text>
- 20. Olver IN, Keech AC. Forming networks for research: proposal for an Australian clinical trials alliance. Med J Aust 2013; 198: 254-255. <MJA full text>
We acknowledge Rhana Pike from the NHMRC Clinical Trials Centre for assistance with the manuscript.
No relevant disclosures.